{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:42:45Z","timestamp":1772210565109,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17ck0106294h0001"],"award-info":[{"award-number":["17ck0106294h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10147-024-02543-x","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T08:01:40Z","timestamp":1715932900000},"page":"1142-1151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study"],"prefix":"10.1007","volume":"29","author":[{"given":"Kaname","family":"Nosaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-357X","authenticated-orcid":false,"given":"Kiyotaka","family":"Yoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Toyozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Morise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadoaki","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyako","family":"Satouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Sakakibara-Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"2543_CR1","unstructured":"National Comprehensive Cancer Network (2023) In: Proceedings of the NCCN Clinical Practice Guidelines in Oncology\u2014Non-Small Cell Lung Cancer, Plymouth, PA, USA"},{"issue":"3","key":"2543_CR2","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3390\/cancers6031540","volume":"6","author":"H Kawakami","year":"2014","unstructured":"Kawakami H, Okamoto I, Okamoto W et al (2014) Targeting MET Amplification as a New Oncogenic Driver. Cancers (Basel) 6(3):1540\u20131552. https:\/\/doi.org\/10.3390\/cancers6031540","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2543_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1158\/0008-5472.CAN-05-2749","volume":"66","author":"M Kong-Beltran","year":"2006","unstructured":"Kong-Beltran M, Seshagiri S, Zha J et al (2006) Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66(1):283\u2013289. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2749","journal-title":"Cancer Res"},{"issue":"8","key":"2543_CR4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","volume":"5","author":"GM Frampton","year":"2015","unstructured":"Frampton GM, Ali SM, Rosenzweig M et al (2015) Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5(8):850\u2013859. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0285","journal-title":"Cancer Discov"},{"issue":"7","key":"2543_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","volume":"34","author":"MM Awad","year":"2016","unstructured":"Awad MM, Oxnard GR, Jackman DM et al (2016) MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression. J Clin Oncol 34(7):721\u2013730. https:\/\/doi.org\/10.1200\/JCO.2015.63.4600","journal-title":"J Clin Oncol"},{"key":"2543_CR6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-1566","author":"LN Mathieu","year":"2021","unstructured":"Mathieu LN, Larkins E, Akinboro O et al (2021) FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1566","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2543_CR7","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf J, Seto T, Han JY et al (2020) Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med 383(10):944\u2013957. https:\/\/doi.org\/10.1056\/NEJMoa2002787","journal-title":"N Engl J Med"},{"issue":"10","key":"2543_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik PK, Felip E, Veillon R et al (2020) Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med 383(10):931\u2013943. https:\/\/doi.org\/10.1056\/NEJMoa2004407","journal-title":"N Engl J Med"},{"issue":"8","key":"2543_CR9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jtho.2016.04.033","volume":"11","author":"SA Noonan","year":"2016","unstructured":"Noonan SA, Berry L, Lu X et al (2016) identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis. J Thorac Oncol 11(8):1293\u20131304. https:\/\/doi.org\/10.1016\/j.jtho.2016.04.033","journal-title":"J Thorac Oncol"},{"issue":"18","key":"2543_CR10","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1021\/jm2007613","volume":"54","author":"JJ Cui","year":"2011","unstructured":"Cui JJ, Tran-Dub\u00e9 M, Shen H et al (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54(18):6342\u20136363. https:\/\/doi.org\/10.1021\/jm2007613","journal-title":"J Med Chem"},{"issue":"24","key":"2543_CR11","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1158\/1078-0432.Ccr-19-0994","volume":"25","author":"L Landi","year":"2019","unstructured":"Landi L, Chiari R, Tiseo M et al (2019) Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): A Phase II, prospective, multicentre, two-arms trial. Clin Cancer Res 25(24):7312\u20137319. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0994","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2543_CR12","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","volume":"30","author":"D Moro-Sibilot","year":"2019","unstructured":"Moro-Sibilot D, Cozic N, P\u00e9rol M et al (2019) Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS\u00e9 phase II trial. Ann Oncol 30(12):1985\u20131991. https:\/\/doi.org\/10.1093\/annonc\/mdz407","journal-title":"Ann Oncol"},{"issue":"1","key":"2543_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","volume":"26","author":"A Drilon","year":"2020","unstructured":"Drilon A, Clark JW, Weiss J et al (2020) Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med 26(1):47\u201351. https:\/\/doi.org\/10.1038\/s41591-019-0716-8","journal-title":"Nat Med"},{"issue":"1","key":"2543_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s13063-020-4221-7","volume":"21","author":"M Shimokawa","year":"2020","unstructured":"Shimokawa M, Nosaki K, Seto T et al (2020) Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study. Trials 21(1):298. https:\/\/doi.org\/10.1186\/s13063-020-4221-7","journal-title":"Trials"},{"key":"2543_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.293","author":"M Schuler","year":"2020","unstructured":"Schuler M, Berardi R, Lim WT et al (2020) Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a Phase I trial. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.293","journal-title":"Ann Oncol"},{"issue":"17","key":"2543_CR16","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"issue":"2","key":"2543_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"issue":"10027","key":"2543_CR18","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/s0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540\u20131550. https:\/\/doi.org\/10.1016\/s0140-6736(15)01281-7","journal-title":"Lancet"},{"issue":"10030","key":"2543_CR19","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/s0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387(10030):1837\u20131846. https:\/\/doi.org\/10.1016\/s0140-6736(16)00587-0","journal-title":"Lancet"},{"issue":"10","key":"2543_CR20","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.jtho.2019.06.023","volume":"14","author":"T Fujino","year":"2019","unstructured":"Fujino T, Kobayashi Y, Suda K et al (2019) Sensitivity and resistance of MET Exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro. J Thorac Oncol 14(10):1753\u20131765. https:\/\/doi.org\/10.1016\/j.jtho.2019.06.023","journal-title":"J Thorac Oncol"},{"key":"2543_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.010","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Otterson GA, Clark JW et al (2021) Crizotinib in patients with MET-amplified NSCLC. J Thorac Oncol. https:\/\/doi.org\/10.1016\/j.jtho.2021.02.010","journal-title":"J Thorac Oncol"},{"issue":"16_suppl","key":"2543_CR22","doi-asserted-by":"publisher","first-page":"9021","DOI":"10.1200\/JCO.2023.41.16_suppl.9021","volume":"41","author":"DS-W Tan","year":"2023","unstructured":"Tan DS-W, Kim TM, Guarneri V et al (2023) Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib. J Clin Oncol 41(16_suppl):9021\u20139021. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9021","journal-title":"J Clin Oncol"},{"issue":"5827","key":"2543_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (New York, NY) 316(5827):1039\u20131043. https:\/\/doi.org\/10.1126\/science.1141478","journal-title":"Science (New York, NY)"},{"issue":"52","key":"2543_CR24","doi-asserted-by":"publisher","first-page":"20932","DOI":"10.1073\/pnas.0710370104","volume":"104","author":"J Bean","year":"2007","unstructured":"Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104(52):20932\u201320937. https:\/\/doi.org\/10.1073\/pnas.0710370104","journal-title":"Proc Natl Acad Sci USA"},{"key":"2543_CR25","doi-asserted-by":"crossref","unstructured":"Kim TMGV, Jye VP, Khaw LB, et al (2023) Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET amplification following 1L Osimertinib: INSIGHT 2 primary analysis. In: Paper presented at the 2023 World Conference on Lung Cancer, Singapore","DOI":"10.1016\/j.jtho.2023.09.106"},{"issue":"18","key":"2543_CR26","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1006448","journal-title":"N Engl J Med"},{"issue":"21","key":"2543_CR27","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Ou SH, Bang YJ et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371(21):1963\u20131971. https:\/\/doi.org\/10.1056\/NEJMoa1406766","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02543-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02543-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02543-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T05:29:23Z","timestamp":1721885363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02543-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2543"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02543-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kaname Nosaki has received research grants from Takeda, AstraZeneca, MSD K.K, Abbvie, Chugai Pharma, DaiichiSankyo\/UCB Japan, and AnHeart Therapeutics and honoraria from AstraZeneca, Chugai Pharma, Lilly, MSD, Pfizer, Taiho Pharmaceutical, Janssen, Ono Pharmaceutical, Takeda, Novartis, and Merck and Advisory Board for Daiichi Sankyo\/UCB Japan and Abbvie. Kiyotaka Yoh has received research grants from Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi sankyo, Lilly, MSD, Pfizer, Taiho, Takeda and consultation for Boehringer Ingelheim and honoraria from Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Daiichi sankyo, Janssen, Kyowa kirin, Lilly, Merck Serono, Novartis, Ono, Otsuka, Taiho, Takeda. Ryo Toyozawa has received research grants from Abbvie, Amgen, AnHeart Therapeutics, Daiichi Sankyo, Eli Lilly Japan, Novartis Pharma, Pfizer Japan, Takeda Pharmaceutical and honoraria from AstraZeneca, Chugai Pharmaceutical, Eli Lilly Japan, MSD, Nippon, Boehringer Ingelheim, Novartis Pharma, Ono Pharmaceutical, Pfizer Japan, Taiho Pharmaceutical, Takeda Pharmaceutical. Hidehito Horinouchi has received research grants from MSD, Abbvie, AstraZeneca, BMS, Ono, Daiichi-Sankyo, Janssen, Chugai, Roche and honoraria from AstraZeneca, MSD, Eli Lilly, Ono, BMS, Chugai, Roche, Amgen, Abbvie and Advisory Board for AstraZeneca, Chugai, Roche, ONO, BMS, Abbvie. Masahiro Morise has received research grants from Boehringer-ingelheim, Eli Lilly and honoraria from Boehringer Ingelheim, Daiichi Sankyo, AstraZeneca, Pfizer, Eli Lilly, Chugai Pharmaceutical, Merk Sharp & Dohme (MSD), Ono Pharmaceutical, and Taiho Pharmaceutical. and Principal investigator of pharmaceutical companies initiated trial for Chugai, Astra Zeneca, Ono, Pfizer, Merk serono, Kissei, Taiho and Novartis. Kadoaki Ohashi has received research grants from Nippon Boehringer Ingelheim Co., Ltd., CHUGAI PHARMACEUTICAL CO., LTD., Eli Lilly Japan K.K., DAIICHI SANKYO COMPANY, LIMITED and honoraria from Eli Lilly Japan K.K., Novartis Pharma K.K., CHUGAI PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd. Haruyasu Murakami has received research grants from Chugai pharma, AstraZeneca, AbbVie, Daiichi Sankyo, IQvia, Taiho Pharmaceutical, Bayer and honoraria from Chugai pharma, Daiichi Sankyo, AstraZeneca, Takeda, Amgen, Ono Pharmaceutical, Bristol-Myers Squibb Japan, MSD, Pfizer, Novartis, Lilly Japan, Taiho Pharmaceutical, Eisai, Nihonkayaku and Advisory Board for Chugai pharma, GAIA BioMedicine, Daiichi Sankyo, Amgen. Miyako Satouchi has received research grants from AstraZeneca, Ono, Bristol Myers Squibb, MSD, Janssen, Amgen, Taiho, Pfizer, Daiichi-Sankyo, Takeda, Eisai, Novartis, GlaxoSmithKline and honoraria from AstraZeneca, Chugai, Eli Lilly, Ono, Bristol Myers Squibb, MSD, Taiho, Pfizer, Novartis, Takeda, Merck, Novartis, Daiichi-Sankyo, Bayer, Amgen, Eisai. Jun Sakakibara-Konishi has received research grants from Lilly. Seiji Yano has received research grants from Takeda, Jansen and honoraria from Pfizer, Chugan, AstraZeneca, Eli Lilly, MSD, Ono, BMS, Amgen, Novartis. Shingo Matsumoto has received research grants from Chugai Pharma, Janssen Pharmaceutical, MSD and honoraria from Eli Lilly, Merck Biopharma, Chugai Pharma, Novartis Pharma, Guardant Health, AstraZeneca. Takashi Seto has received honoraria from Amgen, AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, MSD, Novartis Pharma, Ono Pharmaceutical, Pfizer Japan, Takeda Pharmaceutical, Towa Pharmaceutical and employee of Precision Medicine Asia. Koichi Goto has received research grants from Amgen Inc., Amgen K.K., Amgen Astellas, BioPharma K.K., AstraZeneca K.K., Bayer Yakuhin, Ltd., Boehringer Ingelheim Japan, Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Craif Inc., DAIICHI SANKYO Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Haihe Biopharma Co., Ltd. Ignyta,Inc., Janssen Pharmaceutical K.K., KISSEI PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd., Life Technologies Japan Ltd., Loxo Oncology, Inc., LSI Medience Corporation., MEDICAL& BIOLOGICAL LABORATORIES CO., LTD., Merck Biopharma Co., Ltd., Merus N.V., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Pfizer R&D Japan G.K., Precision Medicine Asia Co., Ltd., RIKEN GENESIS CO., LTD., Sumitomo Pharma Co., Ltd., Spectrum Pharmaceuticals, Inc., Sysmex Corporation., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Turning Point Therapeutics,Inc., Xcoo, Inc. and honoraria from Amgen K.K., Amoy Diagnosties Co.,Ltd., AstraZeneca K.K., Bayer U.S., Boehringer Ingelheim Japan, Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., DAIICHI SANKYO Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Guardant Health Inc., Janssen Pharmaceutical K.K., Merck Biopharma Co., Ltd., Nippon Kayaku Co.,Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., RIKEN GENESIS CO., LTD., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Thermo Fisher Scientific K.K. and Advisory Board for Amgen Inc., Amgen K.K., DAIICHI SANKYO Co., Ltd., Eli Lilly Japan K.K., Haihe Biopharma Co., Ltd., Janssen Pharmaceutical K.K., SYNEOS HEALTH CLINICAL K.K.. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}